Probiodrug AG announced that effective October 31, 2018, and with the contractual termination of her current agreement, Dr. Inge Lues' term as Chief Development Officer will come to an end. She is succeeded by Dr. Michael Schaeffer, who was promoted to Chief Business Officer, effective October 1, 2018. Drawing on his extensive experience in neurology projects across all stages of development, Dr. Schaeffer will additionally take over Probiodug's R&D division following the departure of Dr. Lues. Dr. Schaeffer joined Probiodrug in August as EVP Business & Strategy. Prior to joining Probiodrug, Dr. Schaeffer was the Founder and Managing Director of CRELUX GmbH and SiREEN AG.